Ceribell Reports 29% Revenue Growth in Q1 2026, Launches Neonate and Pediatric EEG Products
核心洞察
Ceribell reported Q1 2026 total revenue of $26.5 million, a 29% increase from $20.5 million in the same period last year, with gross margin of 87%.
The company initiated the commercial launch of neonate and pediatric products following a successful pilot, expanding its seizure (搜索) monitoring platform to patients of all ages.
CMS issued a supportive proposed rule for NTAP reimbursement for Ceribell's delirium (搜索) monitoring solution, with a final rule expected in August 2026.
Ceribell, Inc. (搜索) (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, reported its first quarter 2026 financial results on May 11, 2026, demonstrating robust commercial momentum and the achievement of key strategic milestones.
Total revenue for the first quarter ended March 31, 2026, reached $26.5 million, representing a 29% increase compared to $20.5 million in the same period of 2025. Product revenue contributed $20.2 million, up 29% from $15.6 million, while subscription revenue grew to $6.3 million, also a 29% increase from $4.9 million in the prior-year quarter.
"Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure (搜索) monitoring platform," said co-founder and CEO Jane Chao, Ph.D.
Pediatric and Neonate Product Launch Marks Major Expansion
In a significant development, Ceribell initiated the commercial launch of its neonate and pediatric products following a successful pilot program. This expansion extends the company's brain monitoring capabilities across the entire age spectrum.
"The launch of our neonate and pediatric offerings represents a major milestone in our commitment to provide critical brain monitoring for patients of all ages," Chao stated. "As we work to redefine the standard of care in seizure (搜索) management, we will continue to invest in innovation and expansion of our clinical indications to advance our mission to make EEG a new vital sign."
Reimbursement Progress for Delirium (搜索) Monitoring
The company received a supportive proposed rule from the Centers for Medicare & Medicaid Services (CMS) regarding New Technology Add-on Payment (NTAP) reimbursement for its delirium (搜索) monitoring solution. A final rule is expected in August 2026, which could further accelerate adoption of the Ceribell System in acute-care settings.
Financial Performance and Operating Metrics
Gross profit for the first quarter was $23.1 million, compared to $18.0 million in the first quarter of 2025. Gross margin remained strong at 87%, compared to 88% in the same period last year. The company ended the quarter with 680 total active accounts, reflecting continued expansion into new accounts and deeper adoption within its existing customer base.
Operating expenses increased 36% to $43.9 million, driven by investments in the commercial organization, increased headcount to support business growth, and legal costs associated with intellectual property enforcement activities, including a patent infringement suit initiated in July 2025 against Natus Medical Incorporated (搜索).
Net loss for the quarter was $19.7 million, or $0.52 per share, compared to a net loss of $12.8 million, or $0.36 per share, in the first quarter of 2025. Adjusted EBITDA loss was $11.2 million, compared to $10.9 million in the prior-year period.
As of March 31, 2026, Ceribell held cash, cash equivalents, and marketable securities totaling $141.2 million.
Raised 2026 Financial Outlook
Ceribell raised its full-year 2026 revenue guidance to a range of $112 million to $116 million, representing growth of approximately 26% to 30% over the company's prior year revenue. This upward revision reflects confidence in the continued commercial traction of the Ceribell System and the anticipated contributions from newly launched pediatric and neonate products.
The Ceribell System is a novel, point-of-care electroencephalography (EEG) platform that combines proprietary, highly portable hardware with artificial intelligence-powered algorithms to enable rapid diagnosis and continuous monitoring of patients with neurological conditions. The system is FDA-cleared for use in detecting seizure (搜索) and delirium (搜索) in intensive care units and emergency rooms across the United States.